Skip to content
On this page:OverviewPublicationsKey papers
PICO Portalanswers from OpenAlex & ORCID

Herman Waldmann

ResearcherPublications, citations & collaboration network

Herman Waldmann is a researcher indexed in PICO Portal from OpenAlex & ORCID.

How many works does Herman Waldmann have?

PICO Portalindexed works

Herman Waldmann has 732 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Herman Waldmann have?

PICO Portalcitation count

Herman Waldmann has 49,412 citations in the OpenAlex counts PICO Portal stores.

What is the h-index of Herman Waldmann?

PICO Portalh-index

Herman Waldmann has an h-index of 118 in OpenAlex.

What is the i10-index of Herman Waldmann?

PICO Portali10-index

Herman Waldmann has an i10-index of 446 in OpenAlex.

What is the ORCID of Herman Waldmann?

PICO Portalorcid

The ORCID for Herman Waldmann is on the source record.

What is the OpenAlex record for Herman Waldmann?

PICO Portalopenalex

The OpenAlex for Herman Waldmann is on the source record.

What are the most-cited papers on Herman Waldmann?

PICO Portalmost cited works
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes
Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler, Chantal Mathieu, Leonard Kaufman, G Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon, Liliane Schandené, Laurent Crenier, Christophe De Block, Jean‐Marie Seigneurin, Pieter De Pauw, Denis Piérard, Ilse Weets, Peppy Rebello, Pru Bird, Eleanor Berrie, Mark R. Frewin, Herman Waldmann, Jean‐François Bach, Daniël Pipeleers, Lucienne Chatenoud
New England Journal of Medicine. 20051,096 CitationsOPEN ACCESS
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Seppo Meri, B. Paul Morgan, Alun Davies, Robert Daniels, Mark G. Olavesen, Herman Waldmann, P J Lachmann
PubMed. 1990547 CitationsOPEN ACCESS
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
Bart Keymeulen, Melanie Walter, Chantal Mathieu, L. Kaufman, Frans Gorus, Robert Hilbrands, Evy Vandemeulebroucke, Ursule Van de Velde, Laurent Crenier, Christophe De Block, Sophie Candon, Herman Waldmann, A G Ziegler, Lucienne Chatenoud, Daniël Pipeleers
Diabetologia. 2010313 CitationsOPEN ACCESS

Related on PICO Portal

470M+ articles · 14-day free trial